Challenges and Strategies for Moving Patients to Injectable Medications

The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

Turner RC , Cull CA , Frighi V , Holman RR . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.

American Association of Clinical Endocrinologists . State of diabetes in America. Available at: http://www.aace.com/pub/StateofDiabetes/DiabetesAmericaReport.pdf. Accessed September 6, 2005.

The Diabetes Control and Complications Trial Research Group . Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567-573.

Salle A , Guilloteau G , Ryan M , Bouhanick B , Ritz P . Effect of insulin treatment on the body composition of type 2 diabetic patients. Diabet Med. 2004;21:1298-1303.

Leese GP , Wang J , Broomhall J , et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-1180.

The Diabetes Control and Complications Trial Research Group . Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.

Purnell JQ , Hokanson JE , Marcovina SM , Steffes MW , Cleary PA , Brunzell JD . Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA. 1998;280:140-146.

Cryer PE , Davis SN , Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.

Kolotkin RL , Crosby RD , Williams GR . Assessing weightrelated quality of life in obese persons with type 2 diabetes. Diabetes Res Clin Pract. 2003;61:125-132.

Cox D , Gonder-Frederick L , McCall A , Kovatchev B , Clarke W. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycemia and hyperglycemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl. 2002;129:20-26.

Geelhoed-Duijvestijn PHLM , Peyrot M , Matthews DR , et al. Physician resistance to prescribing insulin: an international study [abstract]. Diabetologia. 2003;46(suppl 2):A274-A275. Abstract 793.

Shah BR , Hux JE , Laupacis A , Zinman B , van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-606.

Funnell MM , Kruger DF . Type 2 diabetes: treat to target. Nurse Pract. 2004;29:11-15, 19-23.

Aventis Pharmaceuticals Inc. Lantus®: insulin glargine [rDNA origin] injection. Available at: http://www.aventis-us.com/PIs/lantus_TXT.html. Accessed August 2, 2005.

Buse J , Henry RR , Han J , et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.

DeFronzo RA , Ratner RE , Han J , Kim DD , Fineman MS , Baron AD . Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.

Kendall DM , Riddle MC , Rosenstock J , et al. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.

Riddle MC . Making the transition from oral to insulin therapy. Am J Med. 2005;118(suppl 5S):S14-S20.

Riddle MC , Rosenstock J , Gerich J , for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.

Raskin P , Allen E , Hollander P , et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.

Feinglos MN , Thacker CH , English J , Bethel MA , Lane JD . Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539-1542.

Eldor R , Stern E , Milicevic Z , Raz I . Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract. 2005;68(suppl 1):S30-S35.

Ryan EA , Imes S , Wallace C . Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27:1028-1032.

Rubin RR . Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5S):S27-S34.

Nichols GA , Gomez A . Weight changes associated with antihyperglycemic therapies for type 2 diabetes [abstract]. Diabetes. 2005;54(suppl 1):A4-A4. Abstract 13-OR.

Kuritzky L , Nelson SE . Assessing the controversies of insulin therapy in patients with type 2 diabetes mellitus. J Fam Pract. 2005;54(suppl):S3-S6.

United Kingdom Prospective Diabetes Study Group . UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.

United Kingdom Prospective Diabetes Study Group . United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.

Fineman MS , Shen LZ , Taylor K , Kim DD , Baron AD . Effectiveness of progressive dose-escalation of exenatide (exendin-4) on glycemic control in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411-417.

Blonde L , Han J , Mac S , Poon T , Taylor K , Kim D . Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes [abstract]. Diabetes Care. 2005;54(suppl 1):A118-A118. Abstract 477-P.

Wilson M , Moore MP , Lunt H . Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Res Clin Pract. 2004;66:263-267.

Mollema ED , Snoek FJ , Ader HJ , Heine RJ , van der Ploeg HM . Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general wellbeing. J Psychosom Res. 2001;51:665-672.

Korytkowski M . When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(suppl 3):S18-S24.

Siminerio L , Zgibor J , Solano FX Jr. Implementing the Chronic Care Model for improvements in diabetes practice and outcomes in primary care: the University of Pittsburgh Medical Center experience. Clin Diabetes. 2004;22:54-58.

Barlow S , Johnson P . Patients use exenatide pen more successfully with educator-led training. Paper presented at: The American Association of Diabetes Educators 32nd Annual Meeting and Exhibition; August 13, 2005; Washington, DC.

Ahern J , Kruger DF , Gatcomb PM , Petit WA Jr , Tamborlane WV . The Diabetes Control and Complications Trial (DCCT): the trial coordinator perspective. Report by the DCCT Research Group. Diabetes Educ. 1989;15:236-241.

Delahanty L , Simkins SW , Camelon K , for the DCCT Research Group . Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. J Am Diet Assoc. 1993;93:758-764.

Janes GR . Ambulatory medical care for diabetes. In: Group NDD , ed. Diabetes in America. Vol. 95-1468. Bethesda, Md: National Institutes of Health; 1995:541-552.

Siminerio L . Implementing diabetes self-management education programs: breaking through the barriers in primary care. Endocr Practice. 2006;12[Suppl 1]:124-130.